Shorting pharmaIt's all about the SEC to be imposing new rules regarding non GAAP reporting as its a practice that has been widely abused in the pharma sector. Results will obviously have material impact on Cxr.
I'm actually hoping this breaks $25 to flush out a lot of the jittery investors and to see if any buyers step in at that point. Personally I will wait until I hear directly from MT as the noise around the possibility of fraudulent practices in cxr is getting really loud.